ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
21 05 2021
Historique:
accepted: 14 04 2021
revised: 12 04 2021
received: 27 05 2020
pubmed: 20 5 2021
medline: 7 7 2021
entrez: 19 5 2021
Statut: ppublish

Résumé

ERG family proteins (ERG, FLI1 and FEV) are a subfamily of ETS transcription factors with key roles in physiology and development. In Ewing sarcoma, the oncogenic fusion protein EWS-FLI1 regulates both transcription and alternative splicing of pre-messenger RNAs. However, whether wild-type ERG family proteins might regulate splicing is unknown. Here, we show that wild-type ERG proteins associate with spliceosomal components, are found on nascent RNAs, and induce alternative splicing when recruited onto a reporter minigene. Transcriptomic analysis revealed that ERG and FLI1 regulate large numbers of alternative spliced exons (ASEs) enriched with RBFOX2 motifs and co-regulated by this splicing factor. ERG and FLI1 are associated with RBFOX2 via their conserved carboxy-terminal domain, which is present in EWS-FLI1. Accordingly, EWS-FLI1 is also associated with RBFOX2 and regulates ASEs enriched in RBFOX2 motifs. However, in contrast to wild-type ERG and FLI1, EWS-FLI1 often antagonizes RBFOX2 effects on exon inclusion. In particular, EWS-FLI1 reduces RBFOX2 binding to the ADD3 pre-mRNA, thus increasing its long isoform, which represses the mesenchymal phenotype of Ewing sarcoma cells. Our findings reveal a RBFOX2-mediated splicing regulatory function of wild-type ERG family proteins, that is altered in EWS-FLI1 and contributes to the Ewing sarcoma cell phenotype.

Identifiants

pubmed: 34009296
pii: 6261781
doi: 10.1093/nar/gkab305
pmc: PMC8136815
doi:

Substances chimiques

ADD3 protein, human 0
Calmodulin-Binding Proteins 0
ERG protein, human 0
EWS-FLI fusion protein 0
FLI1 protein, human 0
Oncogene Proteins, Fusion 0
Proto-Oncogene Protein c-fli-1 0
RBFOX2 protein, human 0
RNA Splicing Factors 0
RNA-Binding Protein EWS 0
Repressor Proteins 0
Transcriptional Regulator ERG 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5038-5056

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

RNA. 2012 May;18(5):1041-9
pubmed: 22456266
Nat Methods. 2006 Dec;3(12):977-9
pubmed: 17099704
Nat Struct Mol Biol. 2016 Jul;23(7):663-72
pubmed: 27273514
Cell. 2017 Sep 21;171(1):163-178.e19
pubmed: 28844694
Nucleic Acids Res. 2016 Jul 8;44(W1):W333-8
pubmed: 27174931
Mol Cell Biol. 2016 May 16;36(11):1704-19
pubmed: 27044866
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Mol Cell. 2017 Feb 2;65(3):539-553.e7
pubmed: 28157508
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell Rep. 2014 May 22;7(4):1211-26
pubmed: 24813895
Oncogene. 2014 Feb 27;33(9):1082-92
pubmed: 23435423
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Genes Cancer. 2012 Feb;3(2):102-16
pubmed: 23050043
Genes Dev. 2008 Sep 15;22(18):2550-63
pubmed: 18794351
Nucleic Acids Res. 2019 Oct 10;47(18):9619-9636
pubmed: 31392992
Cell. 2017 Jul 13;170(2):312-323.e10
pubmed: 28708999
Cell. 2013 Mar 14;152(6):1252-69
pubmed: 23498935
Biomed Res Int. 2018 May 16;2018:3465929
pubmed: 29862265
Annu Rev Biochem. 2011;80:437-71
pubmed: 21548782
Nucleic Acids Res. 2000 Sep 15;28(18):3442-4
pubmed: 10982861
PLoS One. 2009;4(3):e4932
pubmed: 19305498
PLoS Genet. 2018 Nov 30;14(11):e1007826
pubmed: 30500808
Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54
pubmed: 18626011
Oncogene. 1993 Jul;8(7):1751-5
pubmed: 8510921
Cancer Cell. 2014 Nov 10;26(5):668-681
pubmed: 25453903
Cancer Cell. 2007 May;11(5):421-9
pubmed: 17482132
Annu Rev Biochem. 2018 Jun 20;87:351-390
pubmed: 29195049
Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37
pubmed: 11715049
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D535-9
pubmed: 16381927
Nat Struct Mol Biol. 2010 Nov;17(11):1358-66
pubmed: 20972445
Oncogene. 2017 Jun 22;36(25):3505-3514
pubmed: 28135250
Trends Biochem Sci. 2018 Aug;43(8):576-592
pubmed: 29941230
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6004-9
pubmed: 18413612
Nature. 1992 Sep 10;359(6391):162-5
pubmed: 1522903
Cancer Res. 1994 Jun 1;54(11):2865-8
pubmed: 8187069
Chem Rev. 2018 Apr 25;118(8):4339-4364
pubmed: 29251915
Cell. 2016 Apr 21;165(3):606-19
pubmed: 27104978
J Biol Chem. 2000 Aug 11;275(32):24865-71
pubmed: 10827180
Wiley Interdiscip Rev RNA. 2017 Mar;8(2):
pubmed: 27748060
Nature. 2013 Jul 11;499(7457):172-7
pubmed: 23846655
Clin Cancer Res. 2007 Apr 15;13(8):2429-40
pubmed: 17438102
Nat Methods. 2011 Nov 29;8(12):990-2
pubmed: 22127214
RNA. 2012 Feb;18(2):274-83
pubmed: 22184459
Nat Commun. 2016 Mar 31;7:10846
pubmed: 27029405
Genes Dev. 2014 Mar 15;28(6):637-51
pubmed: 24637117
Science. 2018 Jul 27;361(6400):
pubmed: 29930090
Mol Cell. 2012 Feb 24;45(4):567-80
pubmed: 22365833
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Cold Spring Harb Perspect Biol. 2019 Aug 1;11(8):
pubmed: 31371351
Nat Struct Mol Biol. 2012 Oct;19(10):1044-52
pubmed: 22983564
Cancer Res. 2005 Dec 15;65(24):11459-68
pubmed: 16357154
Cell. 2000 Dec 22;103(7):1121-31
pubmed: 11163187
J Biol Chem. 2001 Jun 22;276(25):22317-22
pubmed: 11301318
PLoS Genet. 2011 Aug;7(8):e1002218
pubmed: 21876675
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1307-16
pubmed: 25737553
Cancer Res. 2000 Mar 15;60(6):1536-40
pubmed: 10749119
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genes Dev. 2017 Sep 15;31(18):1910-1925
pubmed: 29021239
Mol Cell Biol. 2013 Jan;33(2):396-405
pubmed: 23149937
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5593-601
pubmed: 25480548
Mol Cell Biol. 2012 Jan;32(2):513-26
pubmed: 22083953
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Elife. 2019 Jul 08;8:
pubmed: 31283468
J Biol Chem. 2006 Jul 14;281(28):19145-55
pubmed: 16698794

Auteurs

Olivier Saulnier (O)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.
Université Paris Diderot, Sorbonne Paris Cité, F-75013 Paris, France.

Katia Guedri-Idjouadiene (K)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Marie-Ming Aynaud (MM)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Alina Chakraborty (A)

Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1278, F-91405 Orsay, France.
Université Paris-Saclay, CNRS UMR3348, INSERM U1278, F-91405 Orsay, France.
Équipe Labellisée Ligue Nationale Contre le Cancer, F-91405 Orsay, France.

Jonathan Bruyr (J)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Joséphine Pineau (J)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Tina O'Grady (T)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Olivier Mirabeau (O)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Sandrine Grossetête (S)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Bartimée Galvan (B)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Margaux Claes (M)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Zahra Al Oula Hassoun (Z)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Benjamin Sadacca (B)

INSERM U932, RT2Lab Team, Translational Research Department, PSL Research University, Institut Curie, F-75005 Paris, France.
CNRS UMR5219, Institut de Mathématiques de Toulouse; Université de Toulouse; F-31062 Toulouse, France.

Karine Laud (K)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Sakina Zaïdi (S)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Didier Surdez (D)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Sylvain Baulande (S)

Institut Curie, PSL Research University, NGS Platform, 26 rue d'Ulm, F-75005 Paris, France.

Xavier Rambout (X)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Franck Tirode (F)

Claude Bernard University Lyon 1, INSERM 1052, CNRS 5286, Cancer Research Center of Lyon (CRCL), Lyon University, Lyon, France.

Martin Dutertre (M)

Institut Curie, PSL Research University, CNRS UMR3348, INSERM U1278, F-91405 Orsay, France.
Université Paris-Saclay, CNRS UMR3348, INSERM U1278, F-91405 Orsay, France.
Équipe Labellisée Ligue Nationale Contre le Cancer, F-91405 Orsay, France.

Olivier Delattre (O)

INSERM U830, Équipe Labellisée LNCC, PSL Research University, SIREDO Oncology Centre, Institut Curie, 75005 Paris, France.

Franck Dequiedt (F)

University of Liège, Interdisciplinary Cluster for Applied Genoproteomics (GIGA), Liège, Belgium.
University of Liège, GIGA-Molecular Biology of Diseases, Liège, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH